© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#kidney cancer

kidneys
Many Advanced Kidney Cancer Patients Don’t Need Surgery
FDA Approves Opdivo Plus Yervoy Combo for Advanced Kidney Cancer
Kidney Cancer 101

Why Are Liver Disease Mortality Trends Shifting?

Better treatments for hepatitis B and C and a lack of such advances for fatty liver or alcoholic liver disease are driving outcomes.
Cancer treatment

Cancer Medications

Cancer cells and lymphocytes

Cancer Appears More Aggressive in People with HIV

HIV-positive individuals are also diagnosed with cancer at later stages than those without the virus.

Hep C Clearly Drives Liver Cancer, but What About Other Cancers?

A new systematic review and meta-analysis indicates that hepatitis C is most notably also associated with B-cell non–Hodgkin lymphoma.

Bavencio Plus Inlyta Gets Green Light for Kidney Cancer

FDA approves immunotherapy plus targeted therapy combo for initial treatment of advanced renal cell carcinoma.
Ed Doelp at a rest stop during an American Cancer Society Bike-a-thon in Philadelphia

A Kidney Cancer Diary

Ed Doelp lives with his wife, Dawn, in Smithville, New Jersey. Now in his 60s, he was diagnosed with kidney cancer in 2012.
Generic image

Kidney Cancer Medications

Here’s a list of the approved drugs to treat kidney cancer. Click on any of the medications for more info on indications, dosing and...

Keytruda Plus Inlyta Gets a New Indication for Kidney Cancer

Immunotherapy and targeted therapy combo is now approved for first-time treatment of advanced renal cell carcinoma.

Votrient

Torisel, temsirolimus

Torisel

Sutent

Inlyta

Opdivo

Mental Health Linked to Higher Death Rates Among Those With Urological Cancers

Mental health care before cancer treatment is associated with higher death rates for those with kidney, prostate or bladder cancer.

New Treatment Combinations Effective for Advanced Kidney Cancer

In two large clinical trials, an immune checkpoint inhibitor combined with a targeted therapy had better outcomes than the standard of care.
Lori Wood, MD

Checkpoint Combos Improve Advanced Kidney Cancer Outcomes

Keytruda and Bavencio may soon join Opdivo/Yervoy as first-line treatment options for advanced renal cell carcinoma.
Advertisement
Treatment News
Newsfeed